KALA BIO (KALA)
NASDAQ:KALA
Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.62
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.62
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$2.03 - $1,030.00
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$67.11M
Enterprise Value$60.63M
Total Cash (Recent Filing)$8.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding18,589,832
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)32.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.08
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.12K
Enterprise Value/Ebitda-3.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-26.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet (no Debt)Elimination of debt materially reduces financial risk and interest burden, improving the company's flexibility to fund clinical programs or seek partnerships. A debt-free stance enhances negotiating power with investors and partners and lowers probability of covenant constraints over the next several quarters.
Focused Antibody PipelineA clear strategic focus on antibody therapeutics for autoimmune and inflammatory diseases provides durable scientific and commercial optionality. Antibody programs benefit from high technical barriers, IP protection potential, and partner interest, supporting long-term value creation if clinical progress continues.
Lean Operating FootprintA small headcount suggests a lean cost structure and likely use of CROs/partners, which can extend runway versus larger in‑house R&D teams. This operational compactness helps preserve capital and prioritize spend on critical clinical milestones over the medium term.
Bears Say
Zero Revenue BaseWith no product revenue, the company lacks a recurring gross-profit foundation, leaving operations entirely dependent on financing or partnerships. This structural absence of commercial cash flow increases execution risk and magnifies the consequences of any funding shortfall over the next 2–6 months.
Heavy, Accelerating Cash BurnConsistent negative operating and free cash flow with an accelerating TTM decline creates a durable financing need. Ongoing cash burn constrains the company's ability to advance multiple programs, raises dilution risk from future financings, and can delay development timelines absent fresh capital.
Persistent Operating LossesSustained operating and net losses indicate the company is far from profitability and generating negative returns on equity. This structural unprofitability increases dependence on external capital and strategic partners, which can limit autonomy and pressure program prioritization over the medium term.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $2.03 and its highest was $1030.00 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $67.11M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on May 19, 2026. The company reported -$0.136 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.136.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 18,589,832 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -$0.136 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.642%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KALA BIO Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 40.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.36%
12-Months-Change
Fundamentals
Return on Equity
-1335.64%
Trailing 12-Months
Asset Growth
-74.47%
Trailing 12-Months
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Ownership Overview
3.61% Insiders
0.36% Mutual Funds
― Other Institutional Investors
96.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---